Outcome of sporadic adenomas and adenoma-like dysplasia in patients with ulcerative colitis undergoing polypectomy

Inflammatory Bowel Diseases

Volumn 18, Issue 2, 2012, Pages 226-235

  Kisiel, John B ^a   Loftus, Edward V ^a   Harmsen, W Scott ^a   Zinsmeister, Alan R ^a   Sandborn, William J ^a  

^a MAYO CLINIC   (United States)

Author keywords

5 aminosalicylic acid; colorectal cancer; colorectal dysplasia; polypectomy; ulcerative colitis

Indexed keywords

ADOLESCENT; ADULT; AGED; ARTICLE; COLON ADENOMA; COLON POLYP; COLORECTAL CANCER; COLORECTAL TUMOR; ENDOSCOPIC POLYPECTOMY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; ULCERATIVE COLITIS;

EID: 84855660082     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1002/ibd.21687     Document Type: Article

References (43)

1. Ekbom A, Helmick C, Zack M, et al. Ulcerative colitis and colorectal cancer. A population-based study. N Engl J Med. 1990; 323: 1228-1233. (Pubitemid 20366527)
2. Broome U, Lindberg G, Lofberg R,. Primary sclerosing cholangitis in ulcerative colitisâ a risk factor for the development of dysplasia and DNA aneuploidy? Gastroenterology. 1992; 102: 1877-1880.
3. Eaden JA, Abrams KR, Mayberry JF,. The risk of colorectal cancer in ulcerative colitis: a meta-analysis. Gut. 2001; 48: 526-535. (Pubitemid 32234798)
4. Kornfeld D, Ekbom A, Ihre T,. Is there an excess risk for colorectal cancer in patients with ulcerative colitis and concomitant primary sclerosing cholangitis? A population based study. Gut. 1997; 41: 522-525.
5. Tytgat GN, Dhir V, Gopinath N,. Endoscopic appearance of dysplasia and cancer in inflammatory bowel disease. Eur J Cancer. 1995; 31A: 1174-1177.
6. Blackstone MO, Riddell RH, Rogers BH, et al. Dysplasia-associated lesion or mass (DALM) detected by colonoscopy in long-standing ulcerative colitis: an indication for colectomy. Gastroenterology. 1981; 80: 366-374. (Pubitemid 11217532)
7. Butt JH, Konishi F, Morson BC, et al. Macroscopic lesions in dysplasia and carcinoma complicating ulcerative colitis. Dig Dis Sci. 1983; 28: 18-26. (Pubitemid 13223398)
8. Engelsgjerd M, Farraye FA, Odze RD,. Polypectomy may be adequate treatment for adenoma-like dysplastic lesions in chronic ulcerative colitis. Gastroenterology. 1999; 117: 1288-1294; discussion 1488-1491.
9. Rubin PH, Friedman S, Harpaz N, et al. Colonoscopic polypectomy in chronic colitis: conservative management after endoscopic resection of dysplastic polyps. Gastroenterology. 1999; 117: 1295-1300.
10. Odze RD, Farraye FA, Hecht JL, et al. Long-term follow-up after polypectomy treatment for adenoma-like dysplastic lesions in ulcerative colitis. Clin Gastroenterol Hepatol. 2004; 2: 534-541. (Pubitemid 38834037)
11. Pekow JR, Hetzel JT, Rothe JA, et al. Outcome after surveillance of low-grade and indefinite dysplasia in patients with ulcerative colitis. Inflamm Bowel Dis. 2010; 16: 1352-1356.
12. Vieth M, Behrens H, Stolte M,. Sporadic adenoma in ulcerative colitis: endoscopic resection is an adequate treatment. Gut. 2006; 55: 1151-1155. (Pubitemid 44085684)
13. Velayos FS, Terdiman JP, Walsh JM,. Effect of 5-aminosalicylate use on colorectal cancer and dysplasia risk: a systematic review and metaanalysis of observational studies. Am J Gastroenterol. 2005; 100: 1345-1353. (Pubitemid 40904360)
14. Moody GA, Jayanthi V, Probert CS, et al. Long-term therapy with sulphasalazine protects against colorectal cancer in ulcerative colitis: a retrospective study of colorectal cancer risk and compliance with treatment in Leicestershire. Eur J Gastroenterol Hepatol. 1996; 8: 1179-1183. (Pubitemid 26413548)
15. Eaden J, Abrams K, Ekbom A, et al. Colorectal cancer prevention in ulcerative colitis: a case-control study. Aliment Pharmacol Ther. 2000; 14: 145-153. (Pubitemid 30088290)
16. Rubin DT, LoSavio A, Yadron N, et al. Aminosalicylate therapy in the prevention of dysplasia and colorectal cancer in ulcerative colitis. Clin Gastroenterol Hepatol. 2006; 4: 1346-1350. (Pubitemid 44716744)
17. Bernstein CN, Blanchard JF, Metge C, et al. Does the use of 5-aminosalicylates in inflammatory bowel disease prevent the development of colorectal cancer? Am J Gastroenterol. 2003; 98: 2784-2788. (Pubitemid 38020124)
18. Rutter M, Saunders B, Wilkinson K, et al. Severity of inflammation is a risk factor for colorectal neoplasia in ulcerative colitis. Gastroenterology. 2004; 126: 451-459. (Pubitemid 38182302)
19. Terdiman JP, Steinbuch M, Blumentals WA, et al. 5-Aminosalicylic acid therapy and the risk of colorectal cancer among patients with inflammatory bowel disease. Inflamm Bowel Dis. 2007; 13: 367-371. (Pubitemid 46668239)
20. Ullman T, Croog V, Harpaz N, et al. Progression to colorectal neoplasia in ulcerative colitis: effect of mesalamine. Clin Gastroenterol Hepatol. 2008; 6: 1225-1230; quiz 1177.
21. Itzkowitz SH, Harpaz N,. Diagnosis and management of dysplasia in patients with inflammatory bowel diseases. Gastroenterology. 2004; 126: 1634-1648. (Pubitemid 38649879)
22. Amonkar MM, Hunt TL, Zhou Z, et al. Surveillance patterns and polyp recurrence following diagnosis and excision of colorectal polyps in a medicare population. Cancer Epidemiol Biomarkers Prev. 2005; 14: 417-421. (Pubitemid 40270106)
23. Velayos FS, Loftus EV Jr, Jess T, et al. Colorectal cancer survival in ulcerative colitis is associated with prior use of 5-aminosalicylic acid but not surveillance colonoscopy (abstract). Gastroenterology. 2006; 130: A2.
24. Clapper ML, Gary MA, Coudry RA, et al. 5-aminosalicylic acid inhibits colitis-associated colorectal dysplasias in the mouse model of azoxymethane/dextran sulfate sodium-induced colitis. Inflamm Bowel Dis. 2008; 14: 1341-1347.
25. Nourani S, Huo D, Strum W, et al. 5-ASA therapy and a lower inflammatory score in chronic ulcerative colitis are associated with a decreased risk of dysplasia and colorectal cancer (abstract). Gastroenterology. 2008; 134: A-660.-
26. Jess T, Loftus EV Jr, Velayos FS, et al. Incidence and prognosis of colorectal dysplasia in inflammatory bowel disease: a population-based study from Olmsted County, Minnesota. Inflamm Bowel Dis. 2006; 12: 669-676. (Pubitemid 44253749)
27. Winawer SJ, Zauber AG, O'Brien MJ, et al. Randomized comparison of surveillance intervals after colonoscopic removal of newly diagnosed adenomatous polyps. The National Polyp Study Workgroup. N Engl J Med. 1993; 328: 901-906. (Pubitemid 23086641)
28. Toruner M, Harewood GC, Loftus EV Jr, et al. Endoscopic factors in the diagnosis of colorectal dysplasia in chronic inflammatory bowel disease. Inflamm Bowel Dis. 2005; 11: 428-434. (Pubitemid 40704076)
29. Itzkowitz SH, Present DH,. Consensus conference: Colorectal cancer screening and surveillance in inflammatory bowel disease. Inflamm Bowel Dis. 2005; 11: 314-321. (Pubitemid 40439686)
30. Bell SM, Kelly SA, Hoyle JA, et al. c-Ki-ras gene mutations in dysplasia and carcinomas complicating ulcerative colitis. Br J Cancer. 1991; 64: 174-178.
31. Rubin CE, Haggitt RC, Burmer GC, et al. DNA aneuploidy in colonic biopsies predicts future development of dysplasia in ulcerative colitis. Gastroenterology. 1992; 103: 1611-1620.
32. Taylor HW, Boyle M, Smith SC, et al. Expression of p53 in colorectal cancer and dysplasia complicating ulcerative colitis. Br J Surg. 1993; 80: 442-444. (Pubitemid 23116077)
33. Brentnall TA, Crispin DA, Rabinovitch PS, et al. Mutations in the p53 gene: an early marker of neoplastic progression in ulcerative colitis. Gastroenterology. 1994; 107: 369-378. (Pubitemid 24233310)
34. Lashner BA, Shapiro BD, Husain A, et al. Evaluation of the usefulness of testing for p53 mutations in colorectal cancer surveillance for ulcerative colitis. Am J Gastroenterol. 1999; 94: 456-462. (Pubitemid 29084669)
35. Sato F, Shibata D, Harpaz N, et al. Aberrant methylation of the HPP1 gene in ulcerative colitis-associated colorectal carcinoma. Cancer Res. 2002; 62: 6820-6822. (Pubitemid 35424066)
36. Ezaki T, Watanabe M, Inoue N, et al. A specific genetic alteration on chromosome 6 in ulcerative colitis-associated colorectal cancers. Cancer Res. 2003; 63: 3747-3749. (Pubitemid 36793062)
37. Aust DE, Haase M, Dobryden L, et al. Mutations of the BRAF gene in ulcerative colitis-related colorectal carcinoma. Int J Cancer. 2005; 115: 673-677. (Pubitemid 40776688)
38. Osborn NK, Zou H, Molina JR, et al. Aberrant methylation of the eyes absent 4 gene in ulcerative colitis-associated dysplasia. Clin Gastroenterol Hepatol. 2006; 4: 212-218. (Pubitemid 43199692)
39. Moriyama T, Matsumoto T, Nakamura S, et al. Hypermethylation of p14 (ARF) may be predictive of colitic cancer in patients with ulcerative colitis. Dis Colon Rectum. 2007; 50: 1384-1392. (Pubitemid 47472402)
40. Dhir M, Montgomery EA, Glockner SC, et al. Epigenetic regulation of WNT signaling pathway genes in inflammatory bowel disease (IBD) associated neoplasia. J Gastrointest Surg. 2008; 12: 1745-1753.
41. Garrity-Park MM, Loftus EV Jr, Bryant SC, et al. Tumor necrosis factor-alpha polymorphisms in ulcerative colitis-associated colorectal cancer. Am J Gastroenterol. 2008; 103: 407-415. (Pubitemid 351248709)
42. Kisiel J, Yab TC, Hussain FT, et al. Noninvasive detection of colorectal neoplasia (CRN) in inflammatory bowel disease (IBD) by stool DNA testing: a pilot study. Gastroenterology. 2010; 138: S-68.
43. Garrity-Park MM, Loftus EV Jr, Sandborn WJ, et al. Methylation status of genes in non-neoplastic mucosa from patients with ulcerative colitis-associated colorectal cancer. Am J Gastroenterol. 2010; 105: 1610-1619.